Prostate Cancer

[unable to retrieve full-text content] Experimental prostate cancer therapy delays disease in 'landmark' trial    CNN First prostate cancer therapy to target genes delays cancer progression    Medical Xpress Targeted therapy slows progression of advanced prostate cancer    EurekAlert Olaparib trial reveals 'first personalized treatment strategy for prostate cancer'    Healio Thousands of British men with advanced prostate cancer are set to get the first 'precision' drug    Daily Mail View full coverage on Google News https://ift.tt/2oM1c0d

[unable to retrieve full-text content] Experimental prostate cancer therapy delays disease in 'landmark' trial    CNN Targeted therapy slows progression of advanced prostate cancer    EurekAlert Podcast Looks At Side Effects Of Prostate Cancer    Radio Ink Olaparib trial reveals 'first personalized treatment strategy for prostate cancer'    Healio First prostate cancer therapy to target genes delays cancer progression    Medical Xpress View full coverage on Google News https://ift.tt/2oM1c0d

Ronald de Wit BARCELONA, Spain — Cabazitaxel significantly improved outcomes compared with androgen receptor-targeted therapies for certain men with previously treated metastatic castration-resistant prostate cancer, according to results of the randomized CARD study presented at European Society for Medical Oncology Congress. Cabazitaxel (Jevtana, Sanofi Genzyme) — a semi-synthetic derivative of a natural taxoid — more than doubled radiographic PFS and reduced risk for death by 36% compared with abiraterone acetate (Zytiga, Janssen) and enzalutamide (Xtandi; Astellas, Pfizer). “This can be considered practice changing,” Ronald de Wit, MD, PhD, full professor at Erasmus Medical Center Cancer Center in the Netherlands, said during his presentation. “These results are both statistically significant and clinically important, and they support the use of cabazitaxel over abiraterone or enzalutamide in this setting.” Taxanes — including docetaxel and cabazitaxel — and androgen-signal

BARCELONA—AstraZeneca and Merck are working hard to bring their PARP inhibitor Lynparza into the prostate cancer arena, and they laid out a second case with new data Monday. The partners presented results at the European Society for Medical Oncology annual meeting showing that among previously treated metastatic, castration-resistant prostate cancer patients with one of three genetic mutations, Lynparza could cut the risk of disease progression or death by a whopping 66%. Men with BRCA1, BRCA2 or ATM mutated cancers went a median 7.4 months without their cancer worsening, versus just 3.6 months for those treated with next-gen therapies such as Johnson & Johnson’s Zytiga or Pfizer and Astellas’ Xtandi. And among men with any of those mutations or one of 12 other mutations in their homologous recombination repair (HRR) genes, Lynparza cut the risk of disease progression or death by 51%. On-Demand Webinar De-Risking the Solid Form Landscape of an API This presentation will

BARCELONA—AstraZeneca and Merck are working hard to bring their PARP inhibitor Lynparza into the prostate cancer arena, and they laid out a second case with new data Monday. The partners presented results at the European Society for Medical Oncology annual meeting showing that among previously treated metastatic, castration-resistant prostate cancer patients with one of three genetic mutations, Lynparza could cut the risk of disease progression or death by a whopping 66%. Men with BRCA1, BRCA2 or ATM mutated cancers went a median 7.4 months without their cancer worsening, versus just 3.6 months for those treated with next-gen therapies such as Johnson & Johnson’s Zytiga or Pfizer and Astellas’ Xtandi. And among men with any of those mutations or one of 12 other mutations in their homologous recombination repair (HRR) genes, Lynparza cut the risk of disease progression or death by 51%. On-Demand Webinar De-Risking the Solid Form Landscape of an API This presentation will

Ronald de Wit BARCELONA, Spain — Cabazitaxel significantly improved outcomes compared with androgen receptor-targeted therapies for certain men with previously treated metastatic castration-resistant prostate cancer, according to results of the randomized CARD study presented at European Society for Medical Oncology Congress. Cabazitaxel (Jevtana, Sanofi Genzyme) — a semi-synthetic derivative of a natural taxoid — more than doubled radiographic PFS and reduced risk for death by 36% compared with abiraterone acetate (Zytiga, Janssen) and enzalutamide (Xtandi; Astellas, Pfizer). “This can be considered practice changing,” Ronald de Wit, MD, PhD, full professor at Erasmus Medical Center Cancer Center in the Netherlands, said during his presentation. “These results are both statistically significant and clinically important, and they support the use of cabazitaxel over abiraterone or enzalutamide in this setting.” Taxanes — including docetaxel and cabazitaxel — and androgen-signal

[unable to retrieve full-text content] Experimental prostate cancer therapy delays disease in 'landmark' trial    CNN https://ift.tt/2oM1c0d

General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission. Late-breaking results from the RADICALS-RT trial ( NCT00541047 / ISRCTN40814031 ), presented at the ESMO Congress in Barcelona, Spain, being held September 27 – October 1, 2019, suggest that men with prostate cancer can be spared radiotherapy after surgery. [1] The study answers a longstanding question about whether the benefits of radiotherapy after surgery outweigh the side-effects. RADICALS-RT is the largest ever trial of postoperative radiotherapy in prostate cancer. It found no difference in disease recurrence at five years between men who routinely had radiotherapy shortly after surgery and men who had radiotherapy later, if the cancer came back. Trial design The RADICALS-RT trial enrolled 1,396 patients after surgery for prostate cancer from the UK, Denmark, Canada, and Ireland. Men were random

Prof Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, USA, study author Credit: © European Society for Medical Oncology Targeting faulty DNA repair mechanisms in advanced castration resistant prostate cancer can slow progression and potentially improve survival, paving the way for a new approach to treatment of the most common form of cancer in men. Data from the PROfound trial, presented at the ESMO Congress 2019, show that olaparib delayed cancer progression by about four months compared to new hormonal agents (enzalutamide or abiraterone acetate) in patients with metastatic, pre-treated prostate cancer whose cancer cells had faulty DNA repair genes. Preliminary data showed that treatment also prolonged overall survival by over three months. "To see such a significant effect on disease progression and other clinically relevant effects such as pain progression and objective response rate is a remarkable achievement in such heav

BARCELONA (Reuters) - AstraZeneca presented results on Monday for a trial of its Lynparza drug against prostate cancer, which it hopes could lead to wider regulatory approval for the treatment for use against more forms of the disease. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid The British drugmaker, together with development partner Merck & Co, said Lynparza was shown to delay disease progression in an aggressive and difficult-to-treat type of prostate cancer by a median 3.8 months in the group most sensitive to the treatment. The data, presented at the annual conference of the European Society for Medical Oncology (ESMO) in Barcelona, adds to further promising results presented on Saturday at the conference that may lead to wider use in women suffering from ovarian cancer. [L5N26J0EH] In the prostate cancer st

'We are now entering a new era of precision medicine for metastatic prostate cancer' Drug extends time to disease progression and potentially survival time, delays time to pain progression There are an estimated 174,650 new cases of prostate cancer with 31,620 deaths in the U.S. in 2019 CHICAGO --- For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large, international phase 3 trial. One of the principal investigators is from Northwestern Medicine. The PROfound trial treated men with metastatic prostate cancer that has progressed after several types of prior therapies, including hormone therapy. This marks a significant advance for prostate cancer treatment, which has lagged behind other common cancers with regard to precision therapy, now the standard of

Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large, international phase 3 trial. One of the principal investigators is from Northwestern Medicine. The PROfound trial treated men with metastatic prostate cancer that has progressed after several types of prior therapies, including hormone therapy . This marks a significant advance for prostate cancer treatment , which has lagged behind other common cancers with regard to precision therapy, now the standard of care in breast, ovarian and lung cancers. "Treatments for metastatic, hormone-resistant prostate cancer have continued to use 'one-size-fits-all' approaches, overlooking the gene

'We are now entering a new era of precision medicine for metastatic prostate cancer' Drug extends time to disease progression and potentially survival time, delays time to pain progression There are an estimated 174,650 new cases of prostate cancer with 31,620 deaths in the U.S. in 2019 CHICAGO --- For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large, international phase 3 trial. One of the principal investigators is from Northwestern Medicine. The PROfound trial treated men with metastatic prostate cancer that has progressed after several types of prior therapies, including hormone therapy. This marks a significant advance for prostate cancer treatment, which has lagged behind other common cancers with regard to precision therapy, now the standard of

MONDAY at noon on "The Source" — Prostate cancer is the second leading cause of cancer death among men in the U.S. What should you know and do to help prevent a diagnosis? Early symptoms for prostate cancer vary. Patients can even be asymptomatic. Difficulty with urination or erectile dysfunction -- commonly mistaken as symptoms of prostate cancer -- are often signs of other diseases, instead. It can be a serious diagnosis but with regular screenings and treatment, the average survival rate is more than 90%. Regular prostate exams are vital for early detection, especially for men age 65 and older. What are the risk factors? What preventative measures or lifestyle changes can be made to avoid a diagnosis? How often should men be screened and what does that process entail? What are the next steps for a man who's received a prostate cancer diagnosis? What medical resources and support groups are available locally? Guests: Dr. Ahmed Mansour , genitourinary oncologist a

BARCELONA, Spain — Radiotherapy can be withheld after surgery for prostate cancer and given only if there are signs of biochemical recurrence of disease, instead of being given automatically to all patients.   This is the new advice from prostate cancer radiation experts discussing new data presented here at the European Society of Medical Oncology annual meeting. These new data include the first results from the largest trial to compare salvage with adjuvant radiotherapy (the RADICALS-RT trial), and also the results of a prospective meta-analysis of three such studies (ARTISTIC). They show that withholding radiotherapy and monitoring men after they have had a prostatectectomy, and giving early salvage radiotherapy (sRT) when the first signs of biochemical recurrence are seen, produces early outcomes that appear to be slightly better than giving adjuvant radiotherapy to all patients. "Maybe 'better than' is not quite the right term to use," commented discussant G

MONDAY at noon on "The Source" — Prostate cancer is the second leading cause of cancer death among men in the U.S. What should you know and do to help prevent a diagnosis? Early symptoms for prostate cancer vary. Patients can even be asymptomatic. Difficulty with urination or erectile dysfunction -- commonly mistaken as symptoms of prostate cancer -- are often signs of other diseases, instead. It can be a serious diagnosis but with regular screenings and treatment, the average survival rate is more than 90%. Regular prostate exams are vital for early detection, especially for men age 65 and older. What are the risk factors? What preventative measures or lifestyle changes can be made to avoid a diagnosis? How often should men be screened and what does that process entail? What are the next steps for a man who's received a prostate cancer diagnosis? What medical resources and support groups are available locally? Guests: Dr. Ahmed Mansour , genitourinary oncologist a

MONDAY at noon on "The Source" — Prostate cancer is the second leading cause of cancer death among men in the U.S. What should you know and do to help prevent a diagnosis? Early symptoms for prostate cancer vary. Patients can even be asymptomatic. Difficulty with urination or erectile dysfunction -- commonly mistaken as symptoms of prostate cancer -- are often signs of other diseases, instead. It can be a serious diagnosis but with regular screenings and treatment, the average survival rate is more than 90%. Regular prostate exams are vital for early detection, especially for men age 65 and older. What are the risk factors? What preventative measures or lifestyle changes can be made to avoid a diagnosis? How often should men be screened and what does that process entail? What are the next steps for a man who's received a prostate cancer diagnosis? What medical resources and support groups are available locally? Guests: Dr. Ahmed Mansour , genitourinary oncologist a

MONDAY at noon on "The Source" — Prostate cancer is the second leading cause of cancer death among men in the U.S.   What are the signs and symptoms? How often should men be screened? Who is most at risk? Early symptoms for prostate cancer vary. Patients can even be asymptomatic. Difficulty with urination or erectile dysfunction -- commonly mistaken as symptoms of prostate cancer -- are often signs of other diseases, instead. It can be a serious diagnosis but with regular screenings and treatment, the average survival rate is more than 90%. Regular prostate exams are vital for early detection, especially for men age 65 and older. What are the risk factors? What preventative measures or lifestyle changes can be made to avoid a diagnosis? How often should men be screened and what does that process entail?   What are the next steps for a man who's received a prostate cancer diagnosis? What medical resources and support groups are available locally? Guests: Dr. Ahme

"Men who struggle with infertility are at much greater risk of prostate cancer," reports the Sun. In a new study, Swedish researchers used their databases to investigate what happened to almost all men who fathered a child over 20 years from 1994 to December 2014. They found men whose babies were born after fertility treatment were more likely to have been diagnosed with prostate cancer in the years since, and more likely to have had prostate cancer at a young age (under 55). The 2 types of fertility treatment considered were IVF, when sperm and eggs are put together in a laboratory to see if the sperm will penetrate and fertilise the egg, and ICSI (intracytoplasmic sperm injection), where sperm is injected directly into the egg. ICSI is most commonly used when there's a problem with the man's sperm. For example, if a man does not produce many sperm or they do not swim well. IVF is sometimes used when the cause of infertility is unknown, or when the problem is w